Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)
August 26 2013 - 5:08AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14D-9
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Onyx
Pharmaceuticals, Inc.
(Name of Subject Company)
Onyx Pharmaceuticals, Inc.
(Names of Persons Filing Statement)
COMMON STOCK,
PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
683399109
(CUSIP Number of Class of Securities)
N. Anthony Coles
President and Chief Executive Officer
Onyx Pharmaceuticals, Inc.
249 East Grand Avenue
South San Francisco, California 94080
(650) 266-0000
With copies to:
Stuart M. Cable
James A. Matarese
Goodwin Procter LLP
Exchange Place
Boston, MA 02109
(617) 570-1000
(Name, address, and telephone numbers of person
authorized to receive notices and communications
on behalf of the persons filing statement)
þ
|
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Onyx Pharmaceuticals, Inc. on August 26, 2013
(including all exhibits attached thereto) is incorporated herein by reference.
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Onyx Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
More Onyx Pharmaceuticals Inc News Articles